Publications by authors named "Alan Stobie"

Claim this Profile
D
Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability.
Patrick S Johnson, Thomas Ryckmans, Justin Bryans, Dave M Beal, Kevin N Dack, Alan Stobie

Bioorg Med Chem Lett· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.
M Jonathan Fray, Paul V Fish, Gillian A Allan, Gerwyn Bish, Nick Clarke, Alan Stobie

Bioorg Med Chem Lett· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological properties of 2-((R-5-chloro-4-methoxymethylindan-1-yl)-1H-imidazole (PF-3774076), a novel and selective alpha1A-adrenergic partial agonist, in in vitro and in vivo models of urethral function.
Kelly Conlon, Clare Christy, Simon Westbrook, Gavin Whitlock, Lee Roberts, Alan Stobie

J Pharmacol Exp Ther· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.
Florian Wakenhut, Gill A Allan, Paul V Fish, M Jonathan Fray, Anthony C Harrison, Alan Stobie

Bioorg Med Chem Lett· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.
Paul V Fish, Florian Wakenhut, Thomas Ryckmans, Alan Stobie

Bioorg Med Chem Lett· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent and selective alpha1A adrenoceptor partial agonists--novel imidazole frameworks.
Gavin A Whitlock, Paul E Brennan, Lee R Roberts, Alan Stobie

Bioorg Med Chem Lett· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.
Paul V Fish, Mark D Andrews, M Jonathan Fray, Alan Stobie, Florian Wakenhut

Bioorg Med Chem Lett· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel 2-imidazoles as potent, selective and CNS penetrant alpha1A adrenoceptor partial agonists.
Lee R Roberts, Justin Bryans, Kelly Conlon, Gordon McMurray, Alan Stobie

Bioorg Med Chem Lett· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Designing rapid onset selective serotonin re-uptake inhibitors. Part 3: Site-directed metabolism as a strategy to avoid active circulating metabolites: structure-activity relationships of (thioalkyl)phenoxy benzylamines.
Donald S Middleton, Mark Andrews, Paul Glossop, Geoffrey Gymer, David Hepworth, Alan Stobie

Bioorg Med Chem Lett· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.
Paul V Fish, Nancy S Barta, David L F Gray, Thomas Ryckmans, Alan Stobie

Bioorg Med Chem Lett· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.
Florian Wakenhut, Paul V Fish, M Jonathan Fray, Ian Gurrell, James E Mills, Alan Stobie

Bioorg Med Chem Lett· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.
Donald S Middleton, Mark Andrews, Paul Glossop, Geoffrey Gymer, David Hepworth, Alan Stobie

Bioorg Med Chem Lett· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel 2-imidazoles as potent and selective alpha1A adrenoceptor partial agonists.
Gavin A Whitlock, Kelly Conlon, Gordon McMurray, Lee R Roberts, Alan Stobie

Bioorg Med Chem Lett· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.
Gavin A Whitlock, Paul V Fish, M Jonathan Fray, Alan Stobie, Florian Wakenhut

Bioorg Med Chem Lett· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.
Paul V Fish, Christopher Deur, Xinmin Gan, Keri Greene, David Hoople, Alan Stobie

Bioorg Med Chem Lett· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors.
Paul V Fish, Thomas Ryckmans, Alan Stobie, Florian Wakenhut

Bioorg Med Chem Lett· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-Benzyl-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-amines as selective dual serotonin/noradrenaline reuptake inhibitors.
Paul V Fish, M Jonathan Fray, Alan Stobie, Florian Wakenhut, Gavin A Whitlock

Bioorg Med Chem Lett· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder.
David C Pryde, Andrew S Cook, Denise J Burring, Lyn H Jones, Stephanie Foll, Alan Stobie

Bioorg Med Chem· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.
M Jonathan Fray, Gerwyn Bish, Alan D Brown, Paul V Fish, Alan Stobie

Bioorg Med Chem Lett· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.
M Jonathan Fray, Gerwyn Bish, Paul V Fish, Alan Stobie, Florian Wakenhut

Bioorg Med Chem Lett· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder. Synthesis and activity of functionalized glutaramides.
David C Pryde, Graham N Maw, Simon Planken, Michelle Y Platts, Vivienne Sanderson, Alan Stobie

J Med Chem· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.
Donald S Middleton, Mark Andrews, Paul Glossop, Geoffrey Gymer, Alan Jessiman, Alan Stobie

Bioorg Med Chem Lett· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of small molecule inhibitors of neutral endopeptidase. Structure-activity studies on functionalized glutaramides.
Graham N Maw, Alan Stobie, Simon Planken, David C Pryde, Vivienne Sanderson

Chem Biol Drug Des· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis